先天性淋巴细胞
医学
炎症
免疫学
关贸总协定3
过敏性炎症
细胞因子
白细胞介素33
MAPK/ERK通路
下调和上调
白细胞介素
信号转导
免疫系统
生物
先天免疫系统
转录因子
基因
生物化学
作者
Xiaogang Zhang,Ziyang Chen,Shaowen Zuo,Hengbiao Sun,Xinyao Li,Xiao Lu,Zhe Xing,Meiqi Chen,Jingping Liu,Gang Xiao,Yumei He
标识
DOI:10.3389/fimmu.2022.835953
摘要
Allergic airway inflammation is a universal airway disease that is driven by hyperresponsiveness to inhaled allergens. Group 2 innate lymphoid cells (ILC2s) produce copious amounts of type 2 cytokines, which lead to allergic airway inflammation. Here, we discovered that both peripheral blood of human and mouse lung ILC2s express the endothelin-A receptor (ETAR), and the expression level of ETAR was dramatically induced upon interleukin-33 (IL-33) treatment. Subsequently, both preventive and therapeutic effects of BQ123, an ETAR antagonist, on allergic airway inflammation were observed, which were associated with decreased proliferation and type 2 cytokine productions by ILC2s. Furthermore, ILC2s from BQ123 treatment were found to be functionally impaired in response to an interleukin IL-33 challenged. And BQ123 treatment also affected the phosphorylation level of the extracellular signal-regulated kinase (ERK), as well as the level of GATA binding protein 3 (GATA3) in activated ILC2s. Interestingly, after BQ123 treatment, both mouse and human ILC2s in vitro exhibited decreased function and downregulation of ERK signaling and GATA3 stability. These observations imply that ETAR is an important regulator of ILC2 function and may be involved in ILC2-driven pulmonary inflammation. Therefore, blocking ETAR may be a promising therapeutic strategy for allergic airway inflammation.
科研通智能强力驱动
Strongly Powered by AbleSci AI